Demographic characteristics, liver/hepatitis B virus test results, fibrosis and treatment of Canadians with chronic hepatitis B, by hepatitis B virus genotype
| Variable | Genotype; no. (%) of patients* (95% CI) | |||||
|---|---|---|---|---|---|---|
| A–E n = 980 | A n = 218 | B n = 278 | C n = 243 | D n = 157 | E n = 84 | |
| Age, yr, mean (median) | 46.2 (44) (45.36–47.01) | 44.8 (43) (43.00–46.70) | 48.3‡ (47) (46.81–49.77) | 49.2‡ (49) (47.61–50.81) | 44.1‡ (42) (41.90–46.27) | 37.9‡ (37.5) (36.14–39.67) |
| Male sex | 533 (54.4) (51.21–57.53) | 121 (55.5) (48.64–62.17) | 143 (51.4) (45.41–57.43) | 127 (52.3) (45.79–58.66) | 95 (60.5) (52.38–68.12) | 47 (56.0) (44.72–66.63) |
| Born in Canada | 3 (0.3) (0.08–0.97) | 0 (0.0)‡ | 1 (0.4) (0.02–2.30) | 2 (0.8)‡ (0.14–3.26) | 0 (0.0) | 0 (0.0) |
| Immigrant status missing | 678 (69.2) (66.17–72.04) | 120 (55.0)‡ (48.18–61.73) | 208 (74.8) (69.21–79.73) | 194 (79.8)‡ (74.12–84.58) | 105 (66.9) (58.86–74.05) | 51 (60.7) (49.43–71.01) |
| Asian | 389 (39.7) (36.63–42.84) | 78 (35.8)‡ (29.50–42.57) | 161 (57.9)‡ (51.86–63.74) | 119 (49.0)‡ (42.55–55.43) | 28 (17.8)‡ (12.37–24.92) | 3 (3.6)‡ (0.93–10.81) |
| Black/African/Caribbean | 128 (13.1) (11.05–15.37) | 43 (19.7)‡ (14.78–25.76) | 1 (0.4)‡ (0.02–2.30) | 5 (2.0)‡ (0.76–5.00) | 20 (12.7)‡ (8.14–19.22) | 59 (70.2)‡ (59.13–79.47) |
| White | 104 (10.6) (8.79–12.75) | 6 (2.8)‡ (1.12–6.18) | 36 (12.9)‡ (9.35–17.61) | 38 (15.6)‡ (11.43–20.96) | 22 (14.0)‡ (9.18–20.66) | 2 (2.4)‡ (0.41–9.14) |
| Ethnicity missing | 333 (34.0) (31.03–37.05) | 91 (41.7)‡ (35.17–48.61) | 80 (28.8)‡ (23.61–34.55) | 81 (33.3)‡ (27.51–39.69) | 63 (40.1)‡ (32.48–48.26) | 18 (21.4)‡ (13.52–32.00) |
| HBeAg positive | 140 (14.3) (12.19–16.67) | 23 (10.6)‡ (6.95–15.60) | 33 (11.9) (8.43–16.40) | 61 (25.1)‡ (19.88–31.13) | 12 (7.6)‡ (4.19–13.27) | 11 (13.1) (7.03–22.64) |
| HBeAg status missing | 233 (23.8) (21.17–26.59) | 64 (29.4)‡ (23.50–35.96) | 62 (22.3) (17.64–27.75) | 53 (21.8)‡ (16.89–27.64) | 33 (21.0)‡ (15.10–28.39) | 21 (25.0) (16.47–35.85) |
| HBV DNA level < 2000 IU/mL | 341 (34.8) (31.83–37.88) | 91 (41.7)‡ (35.17–48.61) | 80 (28.8)‡ (23.61–34.55) | 76 (31.3) (25.58–37.57) | 62 (39.5) (31.88–47.62) | 32 (38.1) (27.91–49.38) |
| HBV DNA level missing | 554 (56.5) (53.36–59.65) | 121 (55.5)‡ (48.64–62.17) | 168 (60.4)‡ (54.40–66.17) | 140 (57.6) (51.12–63.86) | 80 (51.0) (42.90–58.97) | 45 (53.6) (42.41–64.41) |
| Alanine transaminase level, U/L, mean (median)† | 38.7 (28) (33.09–44.23) | 34.6 (27) (29.84–39.37) | 32.0‡ (28) (28.80–35.16) | 52.7 (28) (31.06–74.31) | 28.6‡ (24) (25.42–31.73) | 51.8 (31) (30.80–72.73) |
| Stage F3–4 fibrosis | 27 (2.8) (1.86–4.04) | 3 (1.4)‡ (0.36–4.30) | 8 (2.9)‡ (1.34–5.81) | 11 (4.5)‡ (2.40–8.18) | 2 (1.3) (0.22–5.00) | 3 (3.6) (0.93–10.81) |
| Fibrosis data missing | 636 (64.9) (61.81–67.87) | 166 (76.1)‡ (69.82–81.53) | 154 (55.4)‡ (49.34–61.30) | 154 (63.4)‡ (56.94–69.38) | 105 (66.9) (58.86–74.05) | 57 (67.8) (56.66–77.40) |
| Lamivudine prescription (at any time) | 28 (2.8) (1.94–4.16) | 1 (0.4)‡ (0.02–2.92) | 11 (4.0) (2.09–7.17) | 11 (4.5) (2.40–8.18) | 5 (3.2) (1.18–7.66) | 0 (0.0) |
| Tenofovir disoproxil prescription (at any time) | 155 (15.8) (13.62–18.29) | 18 (8.2)‡ (5.11–12.94) | 36 (12.9) (9.35–17.61) | 68 (28.0)‡ (22.53–34.15) | 25 (15.9) (10.76–22.81) | 8 (9.5) (4.50–18.41) |
| Entecavir prescription (at any time) | 35 (3.6) (2.54–4.99) | 2 (0.9)‡ (0.16–3.63) | 15 (5.4) (3.16–8.93) | 12 (4.9) (2.70–8.68) | 5 (3.2) (1.18–7.66) | 1 (1.2) (0.06–7.37) |
| Treatment data missing | 13 (1.3) (0.74–2.32) | 0 (0.0)‡ | 5 (1.8) (0.66–4.39) | 5 (2.0) (0.76–5.00) | 2 (1.3) (0.22–5.00) | 1 (1.2) (0.06–7.37) |
Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus.
↵† Data missing for 381 patients: 70 with genotype A, 105 with genotype B, 103 with genotype C, 70 with genotype D and 33 with genotype E.
↵‡ p < 0.05 for difference between a given genotype, and the total for all other genotypes minus the value for that genotype.